Kahla, Germany Clinical Trials

This is a Phase 2, single arm study of a tailored immunotherapy approach with nivolumab in adult ( 18 years) subjects with previously untreated (1st line) or pretreated (2nd and 3rd line), surgically unresectable or metastatic TCC (further designated "advanced TCC"). The study targets to recruit 130 untreated (1st line) ...

Aim of the Pentaglobin registry of adult critically ill patients with severe infections is primarily to assess the effects of IVIgAM on the aforementioned outcome parameters and its side effects under real-life conditions based on a prospective, high-quality data documentation Age 18 years Diagnosis of severe bacterial infection Pentaglobin use ...

This is a double-blind, placebo-controlled, randomized, multicenter proof of concept and dose-finding phase II study using two doses of ADRECIZUMAB in patients with early septic shock and a bio-ADM plasma concentration at admission of > 70 pg/ml. "Early" septic shock is defined as a life-threatening organ dysfunction due to dysregulated ...

The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely active Crohn's disease (CD).

Patients aged 12 to under 18 may be included where enrollment of pediatric patients in this study is considered observational and is permissible by local regulations.

This is a randomized, open-label, active-controlled, prospective, multinational Phase III confirmative study with 2 treatment groups and an adaptive design (Bauer and Khne, 1994). The study is designed to compare the efficacy of treatment with abnobaVISCUM 900 with Mitomycin C (MMC). Patients with completely resected superficial bladder carcinoma (Stage Ta) ...

This is a phase II/III multicenter, prospective, randomized, placebo-controlled, double-blind, parallelgroup clinical trial with an adaptive design (flexible group sequential design with adaptive dose selection) in subjects with PPS. This study will consist of two stages. The first stage (Stage 1) is for dose selection, and the second stage (Stage ...

The prospective clinical phase II protocol MC-FludT.16/NM is to be conducted to verify safety and efficacy of Treosulfan-based conditioning compared to Busulfan-based conditioning in paediatric patients. Based on the given clinical experience with either Treosulfan-based or Busulfan-based conditioning in combination with Fludarabine no increased risk for graft failure is expected ...

Heart transplantation is considered the gold-standard therapy for end-stage systolic heart failure but the shortage of donor hearts in Germany and other countries has led to widespread use of left ventricular assist devices (LVAD). Even on the transplant list, patients' condition often deteriorate due to worsening heart failure so that ...

Dilated cardiomyopathy (DCM) is characterized by ventricular chamber enlargement and systolic dysfunction with normal LV wall thickness. According to reports heretofore, the incidence of this disorder in industrialized Western countries lies within the order of magnitude of 5 - 8 new illnesses per year for every 100,000 population. The prevalence, ...